Moderna (MRNA) traded higher in the premarket on Thursday after the Cambridge, Massachusetts-based biotech exceeded Street ...

Less than two years after snapping up the chief commercial role at Moderna, Arpa Garay is stepping aside amid a shake-up in the Big Biotech’s commercial unit. Moderna, a long-time biotech unicorn with ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

CAMBRIDGE, MA / ACCESSWIRE / May 2, 2023 /Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an ...

Moderna MRNA incurred a loss of 51 cents per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate ...

Announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the recent announcement of expansion in the Asia-Pacific region Local commercial ...

Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.

As Moderna awaits the arrival of the commercial COVID-19 vaccine market in the U.S., the toll of waning demand worldwide has become painfully apparent. For all of 2022, the mRNA specialist logged a $1 ...

Corinne Le Goff has been appointed president, CEO and director at Celsion, the clinical-stage biotech announced. Michael Tardugno, the company’s former president and CEO, will continue to serve as ...

Moderna announced Tuesday that it has hired Chantal Friebertshäuser as SVP of commercial for Europe, the Middle East and Canada. Most recently, Friebertshäuser served in global commercial leadership ...

CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join ...